SCHEMBL24256612

SCHEMBL24256612

CCCc1nc2sc(C(=O)NCCc3ccc(OC)c(OC)c3)c(N)c2c2c1CCC2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 1/20 0.60
SMN1; SMN2 Q16637 3/20 0.57
LMNA P02545 3/20 0.57
HPGD P15428 1/20 0.57
MAPT P10636 4/20 0.50
ALDH1A1 P00352 3/20 0.50
GAA P10253 3/20 0.50
KDM4E B2RXH2 2/20 0.50
GLA P06280 2/20 0.50
RXFP1 Q9HBX9 1/20 0.50
PARP1 P09874 3/20 0.49
USP28 Q96RU2 1/20 0.49
USP25 Q9UHP3 1/20 0.49
KMT2A Q03164 1/20 0.49
NAMPT P43490 2/20 0.48
CDK8 P49336 1/20 0.48
CDK19 Q9BWU1 1/20 0.48
ATM Q13315 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256709 0.99 MTOR (0.61) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24256707 0.94 MTOR (0.58) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24256858 0.89 MTOR (0.63) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24256669 0.88 MTOR (0.48) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24256358 0.87 KDM4E (0.52) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24256362 0.87 HPGD (0.52) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL24256357 0.87 MTOR (0.53) MTORSMN1; SMN2LMNAHPGDMAPT
SCHEMBL26780707 0.86 KDM4E (0.51) MTORLMNAHPGDMAPTALDH1A1
SCHEMBL26785483 0.86 KDM4E (0.56) LMNAHPGDMAPTALDH1A1GAA
SCHEMBL24256889 0.86 MTOR (0.46) MTORSMN1; SMN2LMNAHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 MTOR 2191/4885SMN1; SMN2 1921/4885LMNA 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.